Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renshen Guben oral liquid for post-COVID-19 fatigue syndrome
ChiCTR2300069518Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Feb 2023
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Renshen Guben in post-COVID syndrome (2 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoint: Chalder scale score at 12 week. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Renshen Guben
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on ChiCTR2300069518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069518.